Collateral for a security interest recorded Apr 4, 2023 (Antares Capital LP).
Term ends Dec 12, 2026 · High confidence
20-year base term ends Dec 12, 2026
Held by Tersera Therapeutics LLC
Filed Dec 12, 2006 as application 11/638,677 · Granted May 25, 2010
Base term, 20 years from filing
Today
2006
2026
Clock starts
Dec 12, 2006
Dec 12, 2006
Term ends
Dec 12, 2026
Dec 12, 2026
Granted
May 25, 2010
May 25, 2010
base term
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,553,840, to Dec 12, 2026. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 12, 2006, when this application, 11/638,677, was filed | Dec 12, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,553,840) | resolves to Dec 12, 2026, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 12, 2026 | High confidence |
This family
| US 7,723,345 | this patent Dec 2026 | Dec 2026 |
| US 8,063,057 | In force Dec 2026 | Dec 2026 |
| US 8,629,156 | In force Dec 2026 | Dec 2026 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 4, 2007 Reel 19110, frame 938 | Devasagayaraj, Arokiasamy; Jin, Haihong; Liu, Qingyun; Marinelli, Brett; Samala, Lakshama; Shi, Zhi-cai; Tunoori, Ashok; Wang, Ying; Wu, Wenxue; Zhang, Chengmin | Lexicon Genetics Incorporated | Assignment of Assignor's Interest |
| Sep 7, 2007 Reel 19799, frame 460 | Zhang, Haiming | Lexicon Genetics Incorporated | Assignment of Assignor's Interest |
| Oct 19, 2009 Reel 23379, frame 949 | Lexicon Genetics Incorporated | Lexicon Pharmaceuticals, Inc. | Change of Name |
| Dec 20, 2017 Reel 44958, frame 377 | Lexicon Pharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Sep 9, 2020 Reel 53721, frame 37 | Tersera Therapeutics LLC | Newstone Capital Partners, LLC | Security Interest |
| Sep 14, 2020 Reel 53767, frame 445 | Biopharma Credit PLC | Lexicon Pharmaceuticals, Inc. | Release of Security Interest |
| Sep 14, 2020 Reel 53763, frame 754 | Lexicon Pharmaceuticals, Inc. | Tersera Therapeutics LLC | Assignment of Assignor's Interest |
| Sep 30, 2020 Reel 53940, frame 1 | Tersera Therapeutics LLC | Midcap Financial Trust, As Agent | Security Interest |
| Apr 4, 2023 Reel 63215, frame 724 | Tersera Therapeutics LLC | Antares Capital LP, as Agent | Security Interest |
| Apr 4, 2023 Reel 63221, frame 546 | Newstone Capital Partners, LLC | Tersera Therapeutics LLC; JDP Therapeutics LLC | Release of Security Interest |
| Apr 4, 2023 Reel 63253, frame 942 | Midcap Financial Trust, As Agent | Tersera Therapeutics LLC | Release of Security Interest |
| Apr 4, 2023 reel/frame not recorded | Newstone Capital Partners, LLC | Tersera Therapeutics LLC | Release of Security Interest |
| Apr 4, 2023 reel/frame not recorded | Newstone Capital Partners, LLC | JDP Therapeutics LLC | Release of Security Interest |
| Apr 5, 2023 Reel 63227, frame 852 | Tersera Therapeutics LLC | Newstone Capital Partners, LLC | Security Interest |
| Jan 7, 2025 Reel 69835, frame 704 | Newstone Capital Partners, LLC | Tersera Therapeutics LLC | Release of Intellectual Property Security Agreement Recorded at R/F 63227/0852 |
| Apr 15, 2026 Reel 75420, frame 453 | Midcap Financial Trust | Tersera Therapeutics LLC, | Release of Intellectual Property Security Agreements at R/F 41939/0487, 46591/0544 and 53940/0001 |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2026
Term ends Dec 12, 2026. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,553,840, ends no earlier than this term, so it caps nothing.
Citations
37
later US patents cite this one
That is top 25% of utility patents granted in 2010 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.